Skip to main content
Healthcare

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Feed excerpt — reported by STAT News

While deaths appear unrelated to Artiva's therapy, they highlight risks as companies seek to apply cancer therapy strategies to autoimmune diseases.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.